Institute of Good Manufacturing Practices India
Global accredited training & certification provider
Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India
Approved Training Partner of Food Safety and Standards Authority of India (FSSAI)
An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India
Empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh
Affiliated with Life Sciences Sector Skills Council (SSC) and Food Industry Sector Skills Council set up by National Skill Development Corporation (NSDC)
Conferred with QUALITY COUNCIL OF INDIA (QCI) – D.L. SHAH NATIONAL QUALITY AWARD & ASSOCHAM Services Excellence Award 2017

Trusted by organizations & training participants in over 30 countries
Training | Certification | Education | Research


DCGI demands stability data for Non-Patented and Proprietary Drugs

In order to maintain quality of drugs, the Drugs Controller General of India (DCGI) has directed all the drug manufacturers to submit the stability data of non-patent and proprietary medicines. At the time of submission of application for grant of permission to manufacture medicines, the manufacturer will now submit stability data of non-patent and proprietary medicines to ensure quality of products. The DCGI in a letter to all UT/State drug controllers, instructed to bring uniform jurisdiction to submit all stability data at the time for grant of license to manufacture non-patented and proprietary drugs.

The Drugs & Cosmetics Act, 1940, is an Act, to regulate import, manufacture, distribution and sale of drugs and cosmetics. The Drugs & Cosmetics Rules, 1945, made under the Act prescribe statuary requirements for grant of license to manufacture for sale and distribution of drugs to ensure safety, efficacy and quality of drugs manufactured and sold in the country. One of the conditions for grant of license to manufacture for sale and distribution of patent or proprietary medicines is that the applicant shall furnish to the licensing authority evidence and data justifying that the medicines are stable under the condition of storage recommended.

In another letter, DCGI has asked all drug manufacturers to submit the report of self -assessment of their units plus a self-certification stating that they are complying with GMP/GLP requirements as laid down by Drugs and Cosmetics Rules, to the state licensing authorities and CDSCO. All drug manufacturers and pharmaceutical associations were requested vide notice no. 7-5/2016/misc/041 dated 23.07.2015 to make self-assessment of their manufacturing units as part of their self-audit and mandatorily share their reports with State Licensing Authorities and CDSCO.

However, CDSCO is yet to receive self-inspection reports from manufacturers.

IGMPI

More

Contact Us